Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Oramed and Premis Biotech Announce use Pill and Spray Trial

<< Previous

Bullboard Posts

Next >>

Comment by bbuddwisserr104on Mar 23, 2021 6:29am

178 Views

Post# 32856397

RE:RE:Oramed and Premis Biotech Announce use Pill and Spray Trial

Thanks1 wrote: Maybe our shaky past is preventing media from covering us. Otherwise can't see why we are overlooked especially with results to date. Maybe we are more of a threat or disruptive.

after doing some DD i can't see were these two companies are using a carrier to transport N.O to the cells infected althouh they are are using a carrier an proteins that do the same as salzmans drug does just not a natural compound to the body like NO if you look at the experts of companies oramed an premas are not nitric oxide experts so i like claritas chances of being the choice of people but not of big pharma imo

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec